Hepatitis C Therapy Clears Virus in 93% of Patients in BMS-Funded Trial
In the continual competition for successful hepatitis C treatments, Bristol-Myers Squibb is trying its hand at its own combination of drugs — daclatasvir, asunaprevir, and beclabuvir. A 12-week dose of the investigational three-drug hepatitis C combi ...